Pharma BD Deal Intelligence
Nuvectis Pharma in-licensed exclusive worldwide ex-China rights to two clinical-stage compounds from Haisco Pharmaceutical Group: NXP100, a once-daily oral Complement Factor B inhibitor with two MAAs under review in China for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oral paradox-breaker BRAF inhibitor in Phase 1b in China for BRAF-mutated solid tumors. Haisco receives up to $40M in upfront/near-term payments, up to $1.421B in milestones, plus tiered royalties.